Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with or without erythropoietin and G-CSF in low/intermediate-1 risk myelodysplastic syndrome
NL-OMON20915Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jun 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, epoetin beta and filgrastim in myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoint: Hematological improvement. Started Jun 2009; status: active, not recruiting.
02
Drugs
lenalidomideepoetin betafilgrastim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON20915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20915.